2025-10-30 - Analysis Report
Okay, here's an analysis of Natera Inc. (NTRA) based on the data you provided. The report is structured as requested, with a summary at the end.

## NTRA (Natera Inc.) Stock Analysis

**Natera Inc. is a diagnostics company specializing in cell-free DNA testing.**

### 1. Performance vs. S&P 500 (VOO)

*   **NTRA Cumulative Return:** 99.54%
*   **VOO Cumulative Return:** 104.30%
*   **Spread (NTRA - VOO):** -6.3%
*   **Spread Range (Max: 174.4, Min: -88.6):**
*   **Relative Spread:** 31.3

**Analysis:** NTRA has underperformed the S&P 500 by 6.3% based on the cumulative returns to date. The relative spread indicates that NTRA's current performance versus VOO is in the lower end of its historical range, suggesting potential for improvement relative to the index.

### 2. Alpha, Beta Analysis

| Year       | CAGR   | MDD    | Alpha   | Beta  | Cap(B) |
| ---------- | ------ | ------ | ------- | ----- | ------ |
| 2015-2017  | -10.0% | 70.1%  | -34.0%  | -0.2  | 1.2    |
| 2016-2018  | 22.0%  | 80.0%  | 6.0%    | 0.1   | 1.9    |
| 2017-2019  | 50.0%  | 80.0%  | 28.0%   | 1.0   | 4.6    |
| 2018-2020  | 186.0% | 80.5%  | 163.0%  | 1.1   | 13.7   |
| 2019-2021  | 96.0%  | 80.5%  | 49.0%   | 1.6   | 12.8   |
| 2020-2022  | -77.0% | 80.5%  | -76.0%  | 0.1   | 5.5    |
| 2021-2023  | -194.0%| 76.6%  | -195.0% | -1.1  | 8.6    |
| 2022-2024  | 8.0%   | 76.6%  | -13.0%  | -1.2  | 21.7   |
| 2023-2025  | 127.0% | 76.6%  | 58.0%   | 0.1   | 26.5   |

**Analysis:**

*   **CAGR:** Varies significantly, showing periods of strong growth (e.g., 2018-2020, 2019-2021, 2023-2025) and substantial declines (e.g., 2020-2022, 2021-2023).
*   **MDD:** Consistently high Maximum Drawdown, indicating significant volatility and risk.
*   **Alpha:** Highly variable Alpha, reflecting periods of outperformance and underperformance relative to the market. The recent periods show positive alpha, which is a good sign.
*   **Beta:** Beta fluctuates, indicating varying degrees of correlation with the market. More recent periods show negative Beta.

### 3. Recent Price Movement

*   **Current Price:** 193.05
*   **Previous Close:** 189.57
*   **Change:** 1.84% (Positive movement)
*   **5-day Moving Average:** 192.16
*   **20-day Moving Average:** 178.23
*   **60-day Moving Average:** 168.97

**Analysis:** The stock is trading above its 5-day, 20-day, and 60-day moving averages, indicating a short-term uptrend. The recent price increase of 1.84% from the previous close confirms this upward momentum.

### 4. Technical Indicators & Expected Return

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 77.35 (Overbought)
*   **PPO:** 0.85
*   **Hybrid Signal:** "Cash 0% - Buy 100% of cash (6 shares - Very Safe)"
*   **Recent (20-day) Relative Divergence Change:** 4.5% (Positive - Short-term increase)
*   **Expected Return (%):** -102.2%

**Analysis:**

*   The Market Risk Indicator suggests that investment is recommended (on the higher end of medium), which is positive.
*   The RSI indicates that the stock is currently overbought, suggesting a potential pullback in the short term.
*   The Hybrid Signal is strongly recommending a "Buy" position, adding confidence to the investment.
*   The positive change in relative divergence suggests a short-term upward trend.
*   The expected return is very negative, indicating long-term underperformance relative to the S&P 500. *This is a crucial consideration.*

The price change from the previous close (1.84%) suggests a notable positive movement, reflecting recent positive news and potentially impacting short-term trading strategies.

### 5. Recent News & Significant Events

*   **Positive Clinical Data:** Strong data from the PROCEED-CRC trial (Business Wire)
*   **Signatera's Impact:** Articles discuss the potential impact of Signatera's positive Phase 3 data on Natera's long-term growth (Simply Wall St.)
*   **Valuation Assessment:** Analysis of Natera's valuation after pivotal clinical data boosts FDA prospects for Signatera (Simply Wall St.)
*   **Q2 Earnings Reflection:** Review of Natera's Q2 earnings in the context of immuno-oncology stocks (StockStory)
*   **Shares Soaring:** Explanation of why Natera shares are increasing (StockStory)

**Analysis:** The news flow is predominantly positive, focusing on strong clinical data for Signatera and its potential impact on the company's growth and valuation.

### 6. Analyst Opinions

*   **Consensus:** Strong Buy
*   **Mean Rating:** 1.50 (~Buy)
*   **Opinions:** 18
*   **Target Price (Avg/High/Low):** 202.50 / 235.00 / 172.00

**Analysis:** Analyst sentiment is very positive, with a strong buy consensus and a mean rating suggesting a "Buy." The average target price of 202.50 suggests potential upside from the current price.

### 7. Recent Earnings Analysis

| 날짜       | EPS    | 매출      |
| ---------- | ------ | --------- |
| 2025-08-08 | -0.74  | 0.55 B$   |
| 2025-05-09 | -0.50  | 0.50 B$   |
| 2024-11-12 | -0.26  | 0.44 B$   |
| 2024-08-09 | -0.30  | 0.41 B$   |
| 2025-08-08 | -0.30  | 0.41 B$   |

**Analysis:**

*   Natera is not yet profitable. EPS is negative across all periods.
*   Revenues are growing consistently, indicating increasing market traction.
*   The most recent EPS is notably worse than the previous quarters.

### 8. Financial Information

| Quarter    | Revenue | Profit Margin |
| ---------- | ------- | ------------- |
| 2025-06-30 | $0.55B  | 63.41%        |
| 2025-03-31 | $0.50B  | 63.12%        |
| 2024-12-31 | $0.48B  | 62.94%        |
| 2024-09-30 | $0.44B  | 61.79%        |
| 2024-06-30 | $0.41B  | 58.83%        |

| Quarter    | Equity  | ROE     |
| ---------- | ------- | ------- |
| 2025-06-30 | $1.25B  | -8.10%  |
| 2025-03-31 | $1.24B  | -5.40%  |
| 2024-12-31 | $1.20B  | -4.50%  |
| 2024-09-30 | $0.88B  | -3.60%  |
| 2024-06-30 | $0.84B  | -4.48%  |

**Analysis:**

*   Revenue is consistently growing.
*   Profit Margins are very high and also increasing, showing excellent operational efficiency.
*   Equity is increasing, demonstrating financial health.
*   ROE is negative, reflecting the company's current lack of profitability.

### 9. Overall Summary

Natera Inc. (NTRA) presents a mixed picture. Here’s a breakdown:

**Positive Factors:**

*   **Strong Revenue Growth:** Consistent increase in quarterly revenue.
*   **High and Increasing Profit Margins:** Excellent operational efficiency.
*   **Positive News Flow:** Recent news is focused on positive clinical trial data for Signatera.
*   **Analyst Sentiment:** Strong Buy consensus with an average target price suggesting upside potential.
*   **Technical Indicators:** MRI is high (High Investment Recommended) and Hybrid Signal recommends buying.
*   **Short-Term Momentum:** Stock is trading above its moving averages, with a recent price increase.

**Negative Factors:**

*   **Lack of Profitability:** Negative EPS and ROE.
*   **High Volatility:** Indicated by high Maximum Drawdown in the historical data.
*   **Overbought Condition:** RSI suggests the stock may be due for a pullback.
*   **Underperformance vs. S&P 500:** Current underperformance and very negative long-term expected return relative to the index.

**Conclusion:**

NTRA is a high-growth, high-risk stock. The recent positive clinical data and analyst sentiment are encouraging, but the company's lack of profitability and underperformance relative to the S&P 500 are significant concerns. The stock may be suitable for investors with a high-risk tolerance who are optimistic about the future growth potential of Signatera and Natera's other diagnostic products. However, the negative expected return and overbought RSI should be considered carefully. Given the long-term negative expected return, it would likely underperform the S&P 500 and should be avoided unless there is a strong belief in a turnaround.

**Recommendation:**

**Neutral to Cautious Buy:** The strong buy consensus and positive news could lead to short-term gains. However, the long-term negative return means there should be caution in the decision.
